US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Chordate Medical’s CEO looks ahead to 2025 — “The exit process is our primary focus”

During 2024, Chordate Medical made progress in establishing Ozilia, a drug-free treatment for chronic migraines and nasal congestion. For example, the company expanded its presence in markets such as Switzerland and Saudi Arabia. BioStock has reached out to CEO Anders Weilandt to learn more about the highlights of 2024 and the goals for the coming year.Read the full article at biostock.se : https://www.biostock.se/en/2024/12/chordate-medicals-ceo-looks-ahead-to-2025-the-exit-process-is-our-primary-focus/ This is a press release from BioStock - Connecting

BioStock: Chordate Medical advances to final phase of exit strategy

Chordate Medical has a clear goal of executing an exit and has now appointed Partner International Switzerland as an advisor to find a buyer and finalize the exit strategy. A key part of this strategy is to establish proof of concept in selected target markets for the migraine treatment Ozilia. Recently, the company has made significant progress in Saudi Arabia, where the migraine treatment has received market approval.BioStock interviews Chordate Medical's CEO, Anders Weilandt, regarding the exit strategy and market advancements. https://www.biostock.se/en/2024/10/chordate-medical-

BioStock: Promising results in Chordate’s follow-up study

Chordate Medical has conducted an initial data analysis in the long-term study PM010 with its migraine treatment Ozilia. According to the company, the results are promising, both in terms of the primary and secondary endpoints. The company’s CEO, Anders Weilandt, shares more about the results in an interview with BioStock.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/promising-results-in-chordates-follow-up-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Focus on market establisment for Chordate

As Chordate Medical reports its second-quarter results, it is no surprise that the spotlight is on the recently signed agreement with Neurolite. The company has already secured an initial order and remains focused on expanding its presence in Switzerland and other key target markets.– Interest among specialists and neurologists is growing, and Ozilia is a unique alternative that an increasing number of migraine care providers are considering, says CEO Anders Weilandt.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/focus-on-market-

BioStock: Chordate Medical enters agreement in Switzerland

Chordate Medical adds Switzerland as a new focus market for the Ozilia migraine treatment entering into a new partnership agreement with Neurolite, a well-established distributor in neurology in Switzerland.– Neurolite has a complete grasp of the entire neurology market, with well-established relationships with a large portion of all relevant customers, says Chordate’s CEO Anders Weilandt.Read the full article at biostock.se : https://www.biostock.se/en/2024/06/chordate-medical-enters-agreement-in-switzerland/ This is a press release from BioStock -

Chordate Medical’s CEO to BioStock: “We are building step by step”

Chordate’s Q1 report shows higher sales and a reduced operating loss compared to the same period last year. The company has also focused on increasing awareness of the migraine treatment Ozilia among investors and the life science industry at various conferences. BioStock contacted CEO Anders Weilandt to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/chordate-medicals-ceo-we-are-building-step-by-step/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Chordate Medical receives patent approval in the US

Chordate Medical will be granted a fourth patent in the US for the migraine treatment Ozilia. In parallel, work is underway to obtain market approval from the FDA. BioStock reached out to CEO Anders Weilandt to learn more about the opportunities in the US market.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/chordate-medical-receives-patent-approval-in-the-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Chordate's board member to BioStock: "Women's health is a concern for society at large"

Caroline Brandberg, a Chordate Medical board member, participated in Feminvest's event FEARLESS in Oslo on April 25th. During the event, she presented the company's treatment method Ozilia for chronic migraine – a condition that tends to affect women more than men.– Migraine is one of the leading conditions among women. To address this, more treatment options are needed, which must be made available and affordable in order for all women to have access to adequate care,  says Brandberg.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/

BioStock: Chordate comments on Q4 and case report

Chordate Medical has published the year-end report for 2023, which showed an increase in sales compared to the previous year. The company has also recently published a case report strengthening the company’s position. The case report describes the experience of a 60-year-old migraine patient who underwent the Ozilia treatment, resulting in reduction in the frequency of migraine days and the level of pain.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/chordate-comments-on-q4-and-case-report/ This is a press release from BioStock -

BioStock: Chordate's CEO presented at Swiss Nordic Bio

On March 7, Swiss Nordic Bio convened for its annual partnering and investor conference, facilitating connections between Nordic and Swiss life science companies, investors, and industrial partners. BioStock took the opportunity to ask a few questions to Anders Weilandt, CEO of Chordate Medical, who attended to present the medtech company.Read the full article and watch the video interview at biostock.se : https://www.biostock.se/en/2024/03/chordates-ceo-presented-at-swiss-nordic-bio/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Chordate continues its marketing activities and exit strategy

In 2023, Chordate Medical has taken steps forward in the commercial progress with the migraine treatment Ozilia. The long-term goal is to sell the company. To continue working towards this goal, the company intends to carry out a rights issue of 41.8 MSEK. BioStock reached out to CEO Anders Weilandt to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/chordate-continues-its-marketing-activities-and-exit-strategy/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Chordate's CSO comments on the start of the PM009 study

The first patient has now been enrolled in Chordate Medical's open pilot study PM009, which aims to evaluate the effect of the company's migraine treatment Ozilia on patients who do not respond to treatment with CGRP inhibitors and other treatment options. BioStock reached out to the company's Clinical Research & Medical Director, Jan Hermansson, to find out more about the study.Read the full article at biostock.se: https://www.biostock.se/en/2023/12/chordates-cso-comments-on-the-start-of-the-pm009-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: Chordate installs system in Germany and launches in the UAE

Chordate Medical has secured an agreement for the installation of the migraine treatment Ozilia at a private specialist clinic in Germany. This follows from the active work of the company's marketing consultants who are introducing the treatment to the German market. In addition, Chordate Medical has recently contracted a market expert in the United Arab Emirates for introduction of the migraine and rhinitis treatment. CEO Anders Weilandt tells us more in an interview.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/chordate-installs-system-in-germany-and-launches-

BioStock: Chordate Medical starts post-market study in four markets

Chordate Medical is currently underway with its clinical post-market study with Ozilia. The study is an important part of the regulatory requirements for CE marking and can also provide valuable data on optimal treatment frequency. BioStock reached out to the company’s Medical Director, Jan Hermansson, to find out more.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/chordate-medical-starts-post-market-study-in-four-markets/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Chordate Medical’s migraine treatment gets attention at congress

Recently, medtech company Chordate Medical participated in the prominent pain congress Deutsche Schmerzkongress in Mannheim, Germany. During the event, they experienced an increased interest in their migraine treatment Ozilia Migraine. This positive reception is expected to strengthen the company’s ongoing marketing activities in Germany, where they previously also conducted a successful patient study. To find out more about the market introduction in Germany and the highlights from the congress, BioStock contacted the company’s CEO Anders Weilandt.Read the full article at biostock.se:

BioStock: Chordate Medical trains leading UK neurology hospital

On October 6-7, Chordate Medical exhibited its product Ozilia Migraine at a neurology symposium held at the large hospital The Walton Centre in Liverpool. In connection with the event, the company also had the opportunity to provide a separate training on the company’s migraine treatment for nurses and specialist doctors. The group initially intends to use the treatment in their private practice, says the company’s CEO Anders Weilandt in an interview.Read the full article at biostock.se: https://www.biostock.se/en/2023/10/chordate-medical-trains-leading-uk-neurology-hospital/ This is

BioStock: Chordate Medical launches the trademark Ozilia

Chordate Medical introduces its new trademark, Ozilia, for the company’s preventive migraine treatment, formerly known as K.O.S. The new brand name will debut in the international arena during the International Headache Congress in Seoul, the largest global gathering of headache and migraine specialists. BioStock had the opportunity to discuss the company’s new trademark with CEO Anders Weilandt.Read the full article at biostock.se: https://www.biostock.se/en/2023/09/chordate-medical-launches-the-trademark-ozilia/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: International specialist congress and upcoming milestones for Chordate Medical

Chordate Medical has once again received the opportunity to present the company’s migraine treatment K.O.S at a scientific congress. This time at the International Headache Congress in Seoul, Korea, on September 14-17. In addition, the investigators in the PM007 study have submitted a manuscript for a scientific article, which CEO Anders Weilandt elaborates on.Read the full article at biostock.se: https://www.biostock.se/en/2023/08/international-specialist-congress-and-upcoming-milestones-for-chordate-medical/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Dr. Hoffmann presented Chordate Medical’s results in the US

Chordate Medical’s PM007 clinical trial show that treatment with Kinetic Oscillation Stimulation is an effective and safe option for the preventative treatment of chronic migraine. Dr. Jan Hoffmann, principal investigator in the study, recently presented the primary outcomes at the American Headache Society Scientific Meeting. In addition, a case study has been presented at a congress in Berlin showing encouraging treatment results for a 45-year-old woman from the PM007 study. BioStock talked to Dr. Hoffmann about his experience from the study and the K.O.S treatment.Read the full article

BioStock: Otto Skolling elected to Chordate Medical’s Board

Recently, Otto Skolling was elected Vice Chairman of the Board of the medical technology company Chordate Medical. Otto Skolling has over 30 years of experience in product development, business development and project management within the pharmaceutical and medical technology industry. BioStock contacted Otto Skolling to find out more about his expectations for the role as Vice Chairman of the Board of Chordate Medical.Read the full article at biostock.se: https://www.biostock.se/en/2023/06/otto-skolling-elected-to-chordate-medicals-board/ This is a press release from BioStock -

BioStock: Chordate’s treatment has effect on allergic rhinitis

A new Italian study shows that Chordate Medical’s treatment K.O.S has positive effects on allergic rhinitis. The treatment in combination with medication improves nasal airflow and decreases symptoms such as congestion, runny nose, itching, and sneezing. Dr Lino Di Rienzo Businco, lead investigator in the study, shared his thoughts on the K.O.S treatment in an interview with BioStock.Watch the interview at biostock.se: https://www.biostock.se/en/2023/06/chordates-treatment-has-effect-on-allergic-rhinitis/ This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: The market in Saudi Arabia opens up for Chordate

Medtech company Chordate Medical has recently received an order for the rhinitis treatment from the private healthcare company Nahdi Care Clinics in Saudi Arabia. The company expects more orders for the product system, both from private and publicly owned hospitals. In addition, the company’s distributor, Janin Medical, is working to obtain market authorisation for Chordate’s migraine treatment.Read the full article at biostock.se: https://www.biostock.se/en/2023/05/the-market-in-saudi-arabia-opens-up-for-chordate/ This is a press release from BioStock - Connecting Innovation &

BioStock Studio: Clinical Trial Investigator in Chordate’s study in chronic migraine

Chordate Medical’s patient study PM007 is completed and the results indicate that Kinetic Oscillation Stimulation is an effective and safe treatment for chronic migraine. One of the Clinical Trial Investigators in the study is Emilia Tauriala, specialist in neurology and CMO at Terveystalo. Emilia joined BioStock’s studio to tell us more about the study design and results. In addition, we got to take part of her view on K.O.S and the benefits compared to current treatments.Watch the interview at biostock.se:https://www.biostock.se/en/2023/04/clinical-trial-investigator-in-chordates-study-

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe